Knight Therapeutics (FRA:04K) Shares Outstanding (EOP): 98.3 Mil (As of Mar. 2026)


FRA:04K Knight Therapeutics Inc FRA:04K
73 GF Score
Price €6.05
GF Value €5.30
! 6 Warning Signs
View Full Analysis

What is Knight Therapeutics Shares Outstanding (EOP)?

Knight Therapeutics FRA:04K 73 Shares Outstanding (EOP) is 98.3 Mil as of Mar. 2026. GuruFocus rates FRA:04K with a GF Score™ of 73/100 and a GF Value™ of €5.30. The stock has 6 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Knight Therapeutics's shares outstanding for the quarter that ended in Mar. 2026 was 98.3 Mil.

Knight Therapeutics's quarterly shares outstanding declined from Dec. 2025 (99.2 Mil) to Mar. 2026 (98.3 Mil). It means Knight Therapeutics bought back shares from Dec. 2025 to Mar. 2026 .

Knight Therapeutics's annual shares outstanding declined from Dec. 2024 (100.0 Mil) to Dec. 2025 (99.2 Mil). It means Knight Therapeutics bought back shares from Dec. 2024 to Dec. 2025 .


Knight Therapeutics  (FRA:04K) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Knight Therapeutics Shares Outstanding (EOP) Related Terms


Knight Therapeutics Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Knight Therapeutics's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Knight Therapeutics Shares Outstanding (EOP) Chart

Knight Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 117.78 112.21 101.17 100.05 99.19

Knight Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 99.45 99.65 99.68 99.19 98.25

FRA:04K vs ZTS, UTHR: Shares Outstanding (EOP) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Knight Therapeutics's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Knight Therapeutics Shares Outstanding (EOP) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Knight Therapeutics's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Knight Therapeutics's Shares Outstanding (EOP) falls into.


FRA:04K
73GF Score
Knight Therapeutics Inc FRA:04K
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Knight Therapeutics Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 98.3 Mil mean?
Knight Therapeutics (FRA:04K) has a Shares Outstanding (EOP) of 98.3 Mil as of Mar. 2026. The total shares a company has outstanding, at period-end. View historical data on Knight Therapeutics and its competitors.
Is Knight Therapeutics' Shares Outstanding (EOP) too high?
Knight Therapeutics' current Shares Outstanding (EOP) is 98.3 Mil. Overall, Knight Therapeutics has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Knight Therapeutics' Shares Outstanding (EOP) compare to ZTS and UTHR?
Knight Therapeutics' Shares Outstanding (EOP) of 98.3 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Drug Manufacturers company?
A good Shares Outstanding (EOP) depends on the Drug Manufacturers industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Knight Therapeutics and its competitors. Knight Therapeutics's current Shares Outstanding (EOP) is 98.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Knight Therapeutics stock overvalued right now?
Knight Therapeutics (FRA:04K) has a current Shares Outstanding (EOP) of 98.3 Mil. The stock's GF Value™ is €5.30, compared to a current price of €6.05 — trading 14.2% above its estimated fair value. The current Shares Outstanding (EOP) is 98.3 Mil. Knight Therapeutics' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Knight Therapeutics (FRA:04K), the current Shares Outstanding (EOP) is 98.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Knight Therapeutics (FRA:04K) Overvalued in 2026?

Based on GuruFocus' analysis, Knight Therapeutics stock appears to be overvalued. The current stock price of €6.05 is trading 14.2% above its estimated GF Value™ of €5.30.

Key valuation signals for FRA:04K:

  • Shares Outstanding (EOP): 98.3 Mil
  • GF Value™: €5.30 vs. price of €6.05 (14.2% above fair value)
  • GF Score™: 73/100 with 6 warning signs

No single metric tells the full story. See the FRA:04K stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Knight Therapeutics Business Description

Other Exchanges KHTRF:USAGUD:Canada
Address 100 Alexis Nihon Boulevard, Suite 600, Saint-Laurent, QC, CAN, H4M 2P2
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and commercializing pharmaceuticalproducts. and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets. The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically, the company generates revenue from Brazil, Canada, Colombia, Argentina, Mexico, Rest of LATAM, and Others, with the majority revenue generated from the Brazil region.
73GF Score

Get the complete analysis for FRA:04K

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.05
Price
€5.30
GF Value